Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intratumoral autologous myeloid dendritic cells plus AS01 and ipilimumab with intravenous nivolumab in solid tumors
2017-003280-35Phase 2Active
- Sponsor
- UZ Brussel
- Start
- Aug 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ipilimumab, nivolumab and RTS,S/AS02D in Nonhematologic neoplasms, sponsored by UZ Brussel. Primary endpoint: Safety. Started Aug 2017; status: active.
02
Drugs
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2017-003280-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003280-35.